Shots:
- Alvotech and Teva have launched Selarsdi (ustekinumab-aekn) injection, a biosimilar to Stelara, to treat psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis across the US
- The FDA has provisionally determined that all Selarsdi presentations can be approved as interchangeable with Stelara after exclusivity expires on Apr 30, 2025. The four approved presentations are 45 mg/0.5 mL & 90 mg/mL prefilled SC syringes, 45 mg/0.5 mL single-dose vials for SC, and 130 mg/26 mL single-dose IV infusion vials
- In August 2020, Teva and Alvotech formed a partnership to commercialize five Alvotech biosimilars exclusively in the US. Alvotech handles development & manufacturing, while Teva manages commercialization
Ref: Alvotech | Image: Alvotech & Teva
Related News:- Alvotech and Teva Report the Regulatory Filing Acceptance for AVT06 (Biosimilar, Eylea) Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
